These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22239669)

  • 1. Waldenström macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005.
    Sekhar J; Sanfilippo K; Zhang Q; Trinkaus K; Vij R; Morgensztern D
    Leuk Lymphoma; 2012 Aug; 53(8):1625-6. PubMed ID: 22239669
    [No Abstract]   [Full Text] [Related]  

  • 2. Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database.
    Castillo JJ; Olszewski AJ; Cronin AM; Hunter ZR; Treon SP
    Blood; 2014 Jun; 123(25):3999-4000. PubMed ID: 24948623
    [No Abstract]   [Full Text] [Related]  

  • 3. Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21
    Weberpals J; Pulte D; Jansen L; Luttmann S; Holleczek B; Nennecke A; Ressing M; Katalinic A; Merz M; Brenner H;
    Haematologica; 2017 Jun; 102(6):e229-e232. PubMed ID: 28280077
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States.
    Pophali PA; Bartley A; Kapoor P; Gonsalves WI; Ashrani AA; Marshall AL; Siddiqui MA; Kyle RA; Go RS
    Br J Haematol; 2019 Mar; 184(6):1014-1017. PubMed ID: 29532912
    [No Abstract]   [Full Text] [Related]  

  • 5. Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.
    Castillo JJ; Olszewski AJ; Hunter ZR; Kanan S; Meid K; Treon SP
    Cancer; 2015 Jul; 121(13):2230-6. PubMed ID: 25757851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.
    Castillo JJ; Olszewski AJ; Kanan S; Meid K; Hunter ZR; Treon SP
    Br J Haematol; 2015 Apr; 169(1):81-9. PubMed ID: 25521528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study.
    Wang H; Chen Y; Li F; Delasalle K; Wang J; Alexanian R; Kwak L; Rustveld L; Du XL; Wang M
    Cancer; 2012 Aug; 118(15):3793-800. PubMed ID: 22139816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
    Hultcrantz M; Pfeiffer RM; Björkholm M; Goldin LR; Turesson I; Schulman S; Landgren O; Kristinsson SY
    J Thromb Haemost; 2014 Nov; 12(11):1816-21. PubMed ID: 25196979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database.
    Castillo JJ; Olszewski AJ; Kanan S; Meid K; Hunter ZR; Treon SP
    Am J Hematol; 2015 Aug; 90(8):696-701. PubMed ID: 25963924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia.
    Olszewski AJ; Chen C; Gutman R; Treon SP; Castillo JJ
    Br J Haematol; 2017 Oct; 179(1):106-115. PubMed ID: 28677830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study.
    Jeong S; Kong SG; Kim DJ; Lee S; Lee HS
    BMC Cancer; 2020 Jul; 20(1):623. PubMed ID: 32620091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia.
    Merlini G; Baldini L; Broglia C; Comelli M; Goldaniga M; Palladini G; Deliliers GL; Gobbi PG
    Semin Oncol; 2003 Apr; 30(2):211-5. PubMed ID: 12720138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy.
    Kastritis E; Kyrtsonis MC; Morel P; Gavriatopoulou M; Hatjiharissi E; Symeonidis AS; Vassou A; Repousis P; Delimpasi S; Sioni A; Michalis E; Michael M; Vervessou E; Voulgarelis M; Tsatalas C; Terpos E; Dimopoulos MA
    Haematologica; 2015 Nov; 100(11):e446-9. PubMed ID: 26294729
    [No Abstract]   [Full Text] [Related]  

  • 14. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Kyriakou C; Canals C; Sibon D; Cahn JY; Kazmi M; Arcese W; Kolbe K; Gorin NC; Thomson K; Milpied N; Niederwieser D; Indrák K; Corradini P; Sureda A; Schmitz N
    J Clin Oncol; 2010 May; 28(13):2227-32. PubMed ID: 20368570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary systemic amyloidosis in patients with Waldenström macroglobulinemia.
    Zanwar S; Abeykoon JP; Ansell SM; Gertz MA; Dispenzieri A; Muchtar E; Sidana S; Tandon N; Rajkumar SV; Dingli D; Go R; Lacy MQ; Kourelis T; Witzig TE; Inwards D; Buadi F; Gonsalves W; Habermann T; Johnston P; Nowakowski G; Kyle RA; Kumar S; Kapoor P
    Leukemia; 2019 Mar; 33(3):790-794. PubMed ID: 30315235
    [No Abstract]   [Full Text] [Related]  

  • 16. Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).
    Simon L; Fitsiori A; Lemal R; Dupuis J; Carpentier B; Boudin L; Corby A; Aurran-Schleinitz T; Gastaud L; Talbot A; Leprêtre S; Mahe B; Payet C; Soussain C; Bonnet C; Vincent L; Lissandre S; Herbrecht R; Kremer S; Leblond V; Fornecker LM
    Haematologica; 2015 Dec; 100(12):1587-94. PubMed ID: 26385211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or less.
    Poulain S; Dervite I; Leleu X; Coiteux V; Duthilleul P; Morel P
    Haematologica; 2008 Jul; 93(7):1109-11. PubMed ID: 18508793
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of hepatitis C virus infection in IgM-type monoclonal gammopathy of uncertain significance and Waldenström macroglobulinemia.
    Veneri D; Aqel H; Franchini M; Meneghini V; Krampera M
    Am J Hematol; 2004 Dec; 77(4):421. PubMed ID: 15551289
    [No Abstract]   [Full Text] [Related]  

  • 19. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
    Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
    J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival.
    Steingrímsson V; Lund SH; Turesson I; Goldin LR; Björkholm M; Landgren O; Kristinsson SY
    Blood; 2015 Mar; 125(13):2174-5. PubMed ID: 25814489
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.